TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35104057

Group type: EXPERIMENTAL
Intervention: Postoperative cognitive testing and lumbar punctures
Number of subjects: 110
Study: 33967063

Group type: EXPERIMENTAL
Intervention: Eccentric muscle strengthening
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 34698822

Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 1340
Study: 33755028

Group type: EXPERIMENTAL
Intervention: W‐SUDs (Woebot for Substance Use Disorders) for 8 weeks
Number of subjects: 101
Study: 33558354

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LS) consisting of an individual combined exercise programme of strength and endurance training and nutritional counselling with regular feedback for 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 36048042

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT) for 16 weeks
Number of subjects: 80
Study: 33493071

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32790844

Group type: EXPERIMENTAL
Intervention: Folinic acid (FA) rescue
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34036915

Group type: EXPERIMENTAL
Intervention: 50 μg/day levothyroxine for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33397249

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg daily for 8 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg daily for 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (capsules like curcumin)
Number of subjects: 90
Study: 35452569

Group type: EXPERIMENTAL
Intervention: 8-week multicomponent care management intervention
Number of subjects: 3
Study: 32800508

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated in-hospital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sacubitril/valsartan initiated post-discharge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Favorable NT-proBNP response at 4 weeks
Number of subjects: 0
Study: 36220382

Group type: EXPERIMENTAL
Intervention: CADe
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: EAC
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: CADe+EAC
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1245
Study: 34278433

Group type: EXPERIMENTAL
Intervention: On-demand oral TDF/emtricitabine for PrEP
Number of subjects: 245
Study: 32364838

Group type: EXPERIMENTAL
Intervention: Silicone Hydrocoated Stent (Coloplast Imajin® hydro)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Percuflex™ Plus Stent (Boston Scientific)
Number of subjects: 141
Study: 35404972

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 13481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13481
Study: 34669884

Group type: EXPERIMENTAL
Intervention: Modified tissue-selecting therapy stapler combined with complete anal canal preservation surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Milligan‐Morgan surgery
Number of subjects: 200
Study: 32312326

Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT) commencing at ≤ 18 weeks' gestation, performed using automated erythrocytapheresis every 6‐10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care arm will only receive transfusion when clinically indicated.
Number of subjects: 50
Study: 36207757

Group type: EXPERIMENTAL
Intervention: PrEP adherence
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alcohol and substance use
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mental health issues
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 35
Study: 34542039

Group type: EXPERIMENTAL
Intervention: Structured Balance Awareness Program (SBAP)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Health Awareness Program (HAP)
Number of subjects: 97
Study: 32813842

Group type: EXPERIMENTAL
Intervention: Reservoir trays
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-reservoir trays
Number of subjects: 46
Study: 35260381

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 11121

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 11121
Study: 34259565

Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 0
Study: 32349353

Group type: EXPERIMENTAL
Intervention: 25 g of potato protein isolate (PP) twice daily (1.6 g/kg/d total protein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control diet (CON) (0.8 g/kg/d total protein)
Number of subjects: 24
Study: 35304396

Group type: EXPERIMENTAL
Intervention: CRT (50.4 Gy with capecitabine) followed by consolidation chemotherapy (six cycles of CapeOx)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Induction chemotherapy (three cycles of CapeOx plus bevacizumab) followed by CRT and consolidation chemotherapy (three cycles of CapeOx)
Number of subjects: 66
Study: 33217854

Group type: EXPERIMENTAL
Intervention: Nursing intervention for reducing depression
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nursing intervention for improving life quality
Number of subjects: 100
Study: 34511492

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (REBFR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-intensity resistance exercise (RE)
Number of subjects: 15
Study: 32988947

Group type: EXPERIMENTAL
Intervention: Adult participants in YKHEMP
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Children participants in YKHEMP
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Adult YKDFN participants
Number of subjects: 2037
Study: 36017934

Group type: EXPERIMENTAL
Intervention: Local simvastatin (SIM) 2.2 mg in methylcellulose (SIM/MCL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylcellulose alone (MCL)
Number of subjects: 50
Study: 33781315

Group type: EXPERIMENTAL
Intervention: Community-based four-phase participatory learning and action (PLA) cycle intervention implemented over 18 months.
Number of subjects: 4680

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 4680
Study: 35872770

Group type: EXPERIMENTAL
Intervention: RBC exchange (3-4 times in 2 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 60
Study: 33468222

Group type: EXPERIMENTAL
Intervention: Huoxiang Zhengqi (HXZQ)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 35762321

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (4 grams daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral oil (comparator)
Number of subjects: 0
Study: 33288862

Group type: EXPERIMENTAL
Intervention: Midostaurin (50 mg twice daily) with standard-of-care (SOC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 60
Study: 35058583

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 400 mg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (both doses)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: olmesartan 20 mg
Number of subjects: 1161
Study: 34363033

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 159702

Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 159702

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 159702

Group type: COMPARATOR
Intervention: Genetically predicted IGF-1 concentration
Number of subjects: 159702
Study: 34574458

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) products (Angelicae Sinensis Radix, Astragali Radix, Salviae Miltiorrhizae Radix et Rhizoma) administered orally for two weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (other CHM products not specified)
Number of subjects: 48
Study: 33217532

Group type: EXPERIMENTAL
Intervention: Controlled assay
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Randomized assay
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Washing of potato strips
Number of subjects: 127

Group type: COMPARATOR
Intervention: Estimated average dietary exposure
Number of subjects: 127
Study: 32224239

Group type: EXPERIMENTAL
Intervention: Mechanical Tricuspid Valve Replacement (MTV)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Bioprosthetic Tricuspid Valve Replacement (BTV)
Number of subjects: 226
Study: 35144297

Group type: EXPERIMENTAL
Intervention: Radioscopically-guided erector spinae plane (ESP) block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound infiltration technique with local anaesthetics
Number of subjects: 0
Study: 32763086

Group type: EXPERIMENTAL
Intervention: SUGAR Handshake (pharmacist-led patient counselling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 32132128

Group type: EXPERIMENTAL
Intervention: Bilingual multimedia instructional materials and community health workers assisting in biospecimen collection
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Community-based participatory approach
Number of subjects: 103
Study: 34763615

Group type: EXPERIMENTAL
Intervention: Brief Relational Therapy (BRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 40
Study: 33706729

Group type: EXPERIMENTAL
Intervention: real a-tDCS (r-tDCS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: sham tDCS (s-tDCS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 38
Study: 33128132

Group type: EXPERIMENTAL
Intervention: Surefire® anti‐reflux catheter
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard microcatheter
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study: 35150156

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.9 mg daily for 6 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Matched placebo for 6 months
Number of subjects: 78
Study: 33675156

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1250mg TID for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 15
Study: 32188111

Group type: EXPERIMENTAL
Intervention: Q10Vital® water-soluble CoQ10 syrup (investigational product)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ubiquinol capsules (comparative product)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ubiquinone capsules (standard product)
Number of subjects: 21
Study: 34637524

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 2979

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 2979

Group type: COMPARATOR
Intervention: ILI vs DSE
Number of subjects: 2979
Study: 33533908

Group type: EXPERIMENTAL
Intervention: CASSY (Computerized Adaptive Screen for Suicidal Youth)
Number of subjects: 4829
Study: 35025537

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Behavioral Activation (BA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sudden Gains
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Depression Spikes
Number of subjects: 300
Study: 32202330

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day Zataria multiflora extract (Z3) for 2 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6 mg/kg/day Zataria multiflora extract (Z6) for 2 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 45
Study: 35457683

Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nemonoxacin vs Moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nemonoxacin vs Moxifloxacin for PTB misdiagnosed as CAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nemonoxacin vs Levofloxacin for PTB misdiagnosed as CAP
Number of subjects: 0
Study: 32107487

Group type: EXPERIMENTAL
Intervention: TIVA (target-controlled infusion of propofol and remifentanil)
Number of subjects: 121

Group type: COMPARATOR
Intervention: BGA (continuous remifentanil infusion and sevoflurane inhalation)
Number of subjects: 121
Study: 34955446

Group type: EXPERIMENTAL
Intervention: GO2 Frailty Score (GO2FS) ≥3 ('severely frail')
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: modified Rockwood Clinical Frailty Scale (mCFS) 5+ ('frail')
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Geriatric-8 (G8) > 14 ('normal')
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: ECOG Performance Status (PS)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: CARG toxicity score
Number of subjects: 514
Study: 35094007

Group type: EXPERIMENTAL
Intervention: Exoskeleton gait training (12 weeks, 36 sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Active Control (standard gait training or no gait training)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive Control (no gait training)
Number of subjects: 25
Study: 32522698

Group type: EXPERIMENTAL
Intervention: Epinephrine ≥3 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Epinephrine <3 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cerebral performance category (CPC) score
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: iFABP levels
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Neurological outcome
Number of subjects: 52
Study: 35364333

Group type: EXPERIMENTAL
Intervention: Zirkus Empathico (ZE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 82
Study: 34544415

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Direct Facility Financing (DFF)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Business-as-usual
Number of subjects: 571
Study: 32708831

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 23
Study: 37306651

Group type: EXPERIMENTAL
Intervention: Transcatheter edge‐to‐edge repair (TEER) with MitraClip plus guideline‐directed medical therapy (GDMT)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Transcatheter edge‐to‐edge repair (TEER) with MitraClip plus GDMT
Number of subjects: 552
Study: 34629244

Group type: EXPERIMENTAL
Intervention: Rigid ring
Number of subjects: 308

Group type: COMPARATOR
Intervention: Flexible band
Number of subjects: 308
Study: 32265346

Group type: EXPERIMENTAL
Intervention: Subomohyoid Anterior Suprascapular Block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interscalene Block
Number of subjects: 0
Study: 35503145

Group type: EXPERIMENTAL
Intervention: Face-to-face mindfulness training (n=40)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Web-based Student Compass program (n=22)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mindfulness practice at least twice a week
Number of subjects: 102
Study: 33856355

Group type: EXPERIMENTAL
Intervention: Virtual reality walking trails with audio-recorded education
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard of care therapy
Number of subjects: 72
Study: 34779137

Group type: EXPERIMENTAL
Intervention: Massage therapy with 5% lavender oil
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo massage therapy with baby oil
Number of subjects: 58
Study: 33882563

Group type: EXPERIMENTAL
Intervention: Zirconium dioxide (ZrO2) crowns
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lithium disilicate (LDS) crowns
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All crowns (ZrO2 and LDS combined)
Number of subjects: 44
Study: 35285912

Group type: EXPERIMENTAL
Intervention: IRF-40 (40 mg iron/d)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IRF-20 (20 mg iron/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 33798801

Group type: EXPERIMENTAL
Intervention: Comparison to attractive Instagram models
Number of subjects: 142

Group type: COMPARATOR
Intervention: Appearance-neutral control condition
Number of subjects: 142
Study: 32320131

Group type: EXPERIMENTAL
Intervention: Developmental International Consultation on Incontinence Questionnaire-Satisfaction (dICIQ-S)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: dICIQ-S
Number of subjects: 410
Study: 33146831

Group type: EXPERIMENTAL
Intervention: Vertical reading training for patients with right HFD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Horizontal reading training for patients with left HFD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vertical reading training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Horizontal reading training
Number of subjects: 21
Study: 32122312

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model (GLMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete case Ï‡2 test
Number of subjects: 0
Study: 35596636

Group type: EXPERIMENTAL
Intervention: Vitamin B2
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: β-carotene
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Retinol (Vitamin A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: α-tocopherol (Vitamin E)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin C and E
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin B1 and B2 urinary excretion
Number of subjects: 57
Study: 35126302

Group type: EXPERIMENTAL
Intervention: Med–STN+GPi–
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Med–STN–GPi+
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Med+STN+GPi–
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Med+STN–GPi+
Number of subjects: 8
Study: 36280934

Group type: EXPERIMENTAL
Intervention: Cervical stabilisation exercises
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isometric exercises programme alone
Number of subjects: 44
Study: 33619178

Group type: EXPERIMENTAL
Intervention: Probability of vaccine efficacy (50%, 70%, or 90%)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Probability of minor side effects (50%, 75%, 90%)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Serious adverse reaction rates (1/100,000, 1/million, 1/100 million)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Announcement of vaccines being 95% effective
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Expected benefit vs. expected side effects
Number of subjects: 1000
Study: 32593069

Group type: EXPERIMENTAL
Intervention: Climbing Intervention (CI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Swimming Intervention (SI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Occupational Therapy Intervention (OTI)
Number of subjects: 33
Study: 36066264

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) therapy
Number of subjects: 11715

Group type: COMPARATOR
Intervention: Oxygen therapy without HFNC
Number of subjects: 11715
Study: 34400532

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35079985

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 33124900

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 µg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: FF/VI 100/25 µg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 10355
Study: 36368914

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg·kg‐1 intravenously)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 33904921

Group type: EXPERIMENTAL
Intervention: mySmartSkin (MSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 35342769

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (canagliflozin) 100 mg/day
Number of subjects: 20019

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (empagliflozin) 10 mg/day
Number of subjects: 20019

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (ertugliflozin) 5 mg/day
Number of subjects: 20019

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (ipragliflozin) 50 mg/day
Number of subjects: 20019

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (luseogliflozin) 2.5 mg/day
Number of subjects: 20019

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (tofogliflozin) 20 mg/day
Number of subjects: 20019
Study: 32168273

Group type: EXPERIMENTAL
Intervention: Pediatric orders requiring drug formulation manipulation (n=3925)
Number of subjects: 15722

Group type: COMPARATOR
Intervention: Adult orders requiring drug formulation manipulation (n=1301)
Number of subjects: 15722
Study: 32975703

Group type: EXPERIMENTAL
Intervention: Mechanical debridement with air‐powder abrasion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined mechanical‐chemical decontamination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chemical decontamination with hydrogen peroxide and chlorhexidine gluconate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20